Page 6 - Division Of Lymphoma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Division of lymphoma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Division Of Lymphoma Today - Breaking & Trending Today

Dr Kambhampati on the Potential Use of Brexu-Cel in Earlier Treatment Lines in MCL

Swetha Kambhampati, MD, discusses how findings from a subgroup analysis of investigating the use of brexucabtagene autoleucel in relapsed/refractory mantle cell lymphoma may support the continued exploration of this agent in earlier lines of therapy. ....

Swetha Kambhampati , Department Of Hematology Hematopoietic Cell Transplantation , Division Of Lymphoma , Hematopoietic Cell Transplantation , Phase 2 Zuma Trial , Relapsed Refractory Mantle Cell Lymphoma , Brexucabtagene Autoleucel Tercartus Brexu Cel , Cart Cell Therapy , Real World Efficacy ,

ASCO 2023: Leukemia and Lymphoma

Results include a landmark study that involved seamless collaboration across adult and pediatric patient groups, leading to a highly diverse study population. Other coverage addresses access to novel therapies and what's coming in the pipeline, including CAR T-cell therapy with tyrosine kinase inhibitors. ....

United States , Baylor College Of Medicine , Rawan Faramand , Al Hadidi , Alex Francisco Herrera , Jason Westin , Christophers Lathan , Andrew Evens , Carona Jacobson , Zanubrutinib Brukinsa , Claire Roddie , Laquisa Hill , Oreofe Odejide , Binod Dhakal , Greg Roloff , H Lee Moffitt , Brentuximab Vedotin , Rutgers Cancer Institute Of New Jersey , Division Of Lymphoma , Bristol Myers Squibb , Drug Administration , American Society Of Clinical Oncology , Harvard Medical School , American Society For Transplantation , Dana Farber Cancer Institute , Study Group ,

Real-World Outcomes With Brexu-Cel Are Consistent With Clinical Data in R/R MCL, Regardless of Prior Treatment

Swetha Kambhampati, MD, explains the need for real-world data on responses to brexu-cel in patients with relapsed/refractory MCL, compares safety and efficacy data from the subgroup analysis with prior results from ZUMA-2, and discusses how these findings support more long-term follow-up in this population. ....

United States , Swetha Kambhampati , Alex Herrera , Department Of Hematology Hematopoietic Cell Transplantation , Division Of Lymphoma , Hematopoietic Cell Transplantation , Cart Cell Therapy , Mantle Cell Lymphoma ,

Herrera Spotlights Key Research Across Hematologic Malignancies From the 2023 ASCO Annual Meeting

Alex Herrera, MD, discussed key data from the SWOG S1826 trial and other important research in hematologic malignancies presented at the 2023 ASCO Annual Meeting. ....

United States , Alex Herrera , Cancer Network , National Clinical Trials Network , Division Of Lymphoma , Children Oncology Group , National Cancer Institute , News Network , Hematopoietic Cell Transplantation , North America , Oncology Group , Hematologic Oncology , Non Hodgkin Lymphoma , Mantle Cell Lymphoma , Pediatric Oncology , Asco 2023 , Hodgkin Lymphoma , Alex Herrera ,

Phase 1b Data Support Continued Investigation of Acalabrutinib Plus BR in MCL

Tycel Phillips, MD, discusses the rationale and design of a phase 1b trial investigating acalabrutinib plus bendamustine and rituximab in patients with mantle cell lymphoma, highlights key efficacy and safety findings in the treatment-naïve and relapsed/refractory patient cohorts, and postulated next steps on the horizon for investigating BTK inhibitors in combination with chemotherapy in this patient population. ....

United States , Tycel Phillips , Division Of Lymphoma , Department Of Hematology , Hematopoietic Cell Transplantation , Mantle Cell Lymphoma ,